Bausch and Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction

All Primary and Secondary Endpoints Were Achieved LAVAL, QC and HEIDELBERG, Germany, April 13, 2021 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("... Biopharmaceuticals, Ophthalmology Bausch Health Companies, Bausch & Lomb, Novaliq, perfluorohexyloctane
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news